Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAYTULLA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and are using contraception (off-label),Treatment of premenstrual dysphoric disorder (PMDD) in women who desire oral contraception (off-label)
Prevention of pregnancy (FDA-approved)
One capsule orally once daily for 24 weeks.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: CYP3A4, sulfation, glucuronidation. Drospirenone: CYP3A4, reduction, sulfation, glucuronidation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
>=90% bound to albumin and alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
3.5 L/kg, indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 87% (immediate-release); TAYTULLA formulation: 79% relative to immediate-release.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. Use with caution in Child-Pugh Class A.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not approved for use in pediatric patients.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects; use with caution due to potential for decreased hepatic, renal, or cardiac function.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (DVT, PE, stroke, MI), hypertension, gallbladder disease, hepatic neoplasia, hyperkalemia (especially in patients with renal/hepatic impairment or on potassium-sparing drugs), depression, impaired glucose tolerance, weight gain, fluid retention, irritability, mood changes.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast cancer, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, known or suspected pregnancy, hypersensitivity to any component, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, heavy smoking and age >35 years.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions are known. Grapefruit juice may theoretically increase estrogen levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol consumption as it may impair liver function and increase VTE risk.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies show a small increased risk of non-cardiac malformations. Second and third trimesters: Associated with fetal harm including cardiovascular and skeletal malformations, and feminization of male fetuses due to estrogenic effects.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Drospirenone and ethinyl estradiol are excreted in human milk in small amounts (M/P ratio not established). Use during lactation is not recommended as it may reduce milk production and composition. Alternative contraception should be considered.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
TAYTULLA is contraindicated in pregnancy; no dose adjustments are applicable as use should be discontinued immediately upon pregnancy detection. No pharmacokinetic studies in pregnancy are available.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
TAYTULLA is a combined hormonal contraceptive containing estetrol (E4) and drospirenone. It is the first contraceptive to use estetrol, a native estrogen with selective tissue activity. Its unique pharmacokinetics allow for a 24/4 regimen with a 4-day hormone-free interval. The progestin drospirenone has antimineralocorticoid activity, which can help reduce water retention and may be beneficial in patients with acne or premenstrual dysphoric disorder. Due to the risk of hyperkalemia, monitor serum potassium in patients on concomitant medications that increase potassium levels, such as ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics. The risk of venous thromboembolism (VTE) is present, and patients should be counseled on symptoms. TAYTULLA is contraindicated in patients with a BMI ≥ 35 kg/m² due to increased VTE risk.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, preferably after the evening meal. The pill pack contains 24 active tablets (white) followed by 4 placebo tablets (yellow).,If you miss a white tablet, take it as soon as you remember, even if it means taking two tablets in one day. If you miss a white tablet for more than one day, use backup contraception for the next 7 days.,This medication does not protect against HIV or other sexually transmitted infections. Use condoms for STI protection.,Common side effects include headache, nausea, breast tenderness, and mood changes. Contact your healthcare provider if you experience severe abdominal pain, chest pain, shortness of breath, or leg pain/swelling, which may indicate a blood clot.,Smoking increases the risk of serious cardiovascular side effects. Women over 35 who smoke should not use this medication.,Inform your healthcare provider of all medications you take, especially those that affect potassium levels (e.g., certain blood pressure medications, NSAIDs, potassium supplements).
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAYTULLA vs AFIRMELLE, answered by our medical review team.
TAYTULLA is a Oral Contraceptive that works by Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAYTULLA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAYTULLA is: One capsule orally once daily for 24 weeks.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAYTULLA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAYTULLA is classified as Category C. TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.